MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Wed, 5 August 2026
What it is about
Furoscix Readyflow AutoinjectorMichael CastagnaFuroscix ReadyflowExchange CommissionMannkind CorporationTerms Of ServiceMannkind Corporation NasdaqDelivery NetworksUnited Therapeutics CorporationManila, Manila, Philippines
Who published it, and when
How it spread - 1 original report
Wed, 5 August 2026
1 report- manilatimes.net20:08first to report
Achieved three major catalysts to drive future growth:Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancementEncouraging early momentum in Afrezza pediatric launch1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025Conference call and webcast today at...